Abstract library

709 results for "Yu-Qing".
#238 Peptide Receptor Radionuclide Therapy (PRRNT) in Patients with Metastasized Neuroendocrine Tumor Having Single or Non-functional Kidney - Is it Safe?
Introduction: Nephrotoxicity is one of the primary concerns in PRRNT of metastasized neuroendocrine tumors (NET).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
#2708 Patient Reported Symptoms, Coping and Quality of Life during Somatostatin Analogue Treatment for Metastatic Small-Intestinal Neuroendocrine Tumours
Introduction: Patients with metastatic small-intestinal neuroendocrine tumours (NET) have been shown to have a reduced quality of life compared to the general population and many have disabling symptoms during somatostatin analogue (SSA) treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof Halfdan Sorbye
#456 Assessment of Quality of Life, Coping Strategies and Beliefs in NET Patients
Introduction: Quality of life (QoL) measurements have been included in clinical trials as a relevant outcome variable; however, other psychological variables might have an impact on QoL.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Mr Jorge Garcia-Hernandez
#631 Genotype – Phenotype Correlations and Timing of Prophylactic Thyroidectomy in Patients with Familial Medullary Thyroid Carcinoma
Introduction: Recommendations on the timing of prophylactic thyroidectomy (PTTE) in patients with familial medullary carcinoma (FMTC) are based on classification of RET mutations into four risk levels (ATA 2009).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: prof. MD, PhD Jan Podoba
#1682 Clinicohistopathological Features and Treatment Outcomes of Neuroendocrine Tumors; A Single Center Experience
Introduction: Neuroendocrine tumors (NETs) are very heterogeneous family of cancers.Tumor and patient characteristics of NETs significantly change between geographical locations that probably induced by environmental and genetic factors throughout the world. Therefore, reporting single center experience may help to clarify epidemiological view and to improve the decision-making process.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Ali Murat Sedef
#1798 Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Patients wth Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: The Prospective, Open-label, International, Phase 2 CLARINET FORTE Study
Introduction: CLARINET demonstrated the antitumour effect of LAN 120mg/28 days (standard interval) in metastatic gastroenteropancreatic NETs. If disease progresses (PD) on this dose, aggressive treatments (eg targeted therapies) are usually offered.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Marianne Pavel
Authors: Pavel M, Dromain C, Majdi A, Houchard A, ...
#1628 What Matters Most? An Exploration of Decision Criteria Considered by Patients with GEP-NET and Physicians Using Holistic Multi-Criteria Decision Analysis
Introduction: Patient-centered care means identifying what matters most through shared decision making. EVIDEM provides an MCDA platform to explore decision criteria and tradeoffs.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: ...none of the above
Presenting Author: Dima Samaha
#2744 Immediate Adverse Effects of Peptide Receptor Radionuclide Therapy (PRRT) Administration in Patients with Neuroendocrine Tumors (NETs): A Single Institution Review
Introduction: PRRT is an effective treatment for well-differentiated NET, but immediate adverse events during or shortly after administration of the treatment are not well defined.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Christopher Wee
Authors: Wee C, Dundar A, Packard A, Kendi A T, ...
#999 Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study
Introduction: Criteria other than RECIST are not validated for evaluation of response during treatment in pancreatic neuroendocrine tumors (pNETs). Preliminary evidence favors antiangiogenic properties of E.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Sara Cingarlini
Keywords: everolimus, pNET, P-CT
#1661 Investigating the Increasing Incidence of Neuroendocrine Tumors in Pakistan as a Result of Increased Awareness
Introduction: Incidence of Neuroendocrine tumors has been increasing worldwide. The reasons for this rising incidence remains unknown.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...